Back

The sodium–glucose co-transporter 2 inhibitor canagliflozin, attenuates cardiac fibrosis and function in inflammatory dilated cardiomyopathy

28 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Risk stratification in idiopathic dilated cardiomyopathy Idiopathic Dilated Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Jingyang Wang

Beijing (China)

7 More presentations in this session

Presentation thumbnail
Diagnostic and prognostic value of exercise-induced ventricular arrhythmias in genetic dilated cardiomyopathy
Miss N. Kalf (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Integrated cardiac magnetic resonance and plasma proteomics for phenotyping and risk stratification in idiopathic dilated cardiomyopathy
Doctor A. Wu (Beijing, CN)
Abstract Slides
Presentation thumbnail
The “negative” side of cardiomyopathy: phenotype and arrhythmic risk in gene-elusive patients
Doctor M. Martini (Padova, IT)
Abstract Slides
Presentation thumbnail
Exercise stress test arrhythmic patterns by genotype in non-desmosomal arrhythmogenic cardiomyopathy
Doctor A. Sularz (Rochester, US)
Abstract Slides
Presentation thumbnail
Dilated cardiomyopathy and isolated right ventricular structural abnormalities in a cohort of SCN5A variant carriers
Miss F. Tuijnenburg (Amsterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Risk stratification in idiopathic dilated cardiomyopathy

The Event

Event poster

ESC Congress 2026

28 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Influence of long-term sodium-glucose cotransporter 2 inhibition on cardiac remodeling in rats with type 1 diabetes mellitus
27 August 2022
thumbnail
Congress Presentation
Genetic regulation of myocardial fibrosis in hypertrophic cardiomyopathy
27 August 2021
thumbnail
Congress Presentation
Colchicine added to standard therapy further reduces fibrosis in pigs with myocardial infarction
21 May 2023
thumbnail
Congress Presentation
The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources